ORBIMED ADVISORS LLC 4
4 · Shattuck Labs, Inc. · Filed Jun 15, 2026
Research Summary
AI-generated summary of this filing
Shattuck Labs (STTK) OrbiMed Advisors Buys 1.25M Shares
What Happened
OrbiMed Advisors LLC (reporting as a director designee) participated in Shattuck Labs' June 2026 public offering, acquiring 1,041,667 common shares and 208,333 pre‑funded warrants on June 11, 2026. The common shares were issued at $4.00 each and the pre‑funded warrants at $3.9999 each, for a combined cash outlay of roughly $5.0 million. This was a purchase (institutional buy) via the offering rather than a sale.
Key Details
- Transaction date: June 11, 2026; Form 4 filed June 15, 2026 (appears 4 days after the trade; may be late under the 2‑business‑day Form 4 rule).
- Securities bought: 1,041,667 common shares @ $4.00; 208,333 pre‑funded warrants @ $3.9999; total ≈ $5.0M.
- Shares owned after transaction: not specified in the provided excerpt of the filing.
- Notable footnotes: offering closed June 11, 2026; pre‑funded warrants are exercisable immediately at $0.0001 per share and subject to a 9.99% beneficial ownership blocker (they expire once exercised).
- Filing parties & structure: securities are held of record by OrbiMed funds (OrbiMed Private Investments IX, LP and OrbiMed Genesis Master Fund, L.P.); OrbiMed Advisors is the managing member and may be deemed to have voting/investment power. OrbiMed designated Mona Ashiya to serve on the issuer’s board; the reporting persons disclaim beneficial ownership except for any pecuniary interest.
Context
These purchases were made in a registered public offering (not open‑market trading). Pre‑funded warrants allow the holder to exercise into common stock at a nominal price ($0.0001) but include a 9.99% ownership blocker that can limit immediate conversion. This filing reports institutional activity by OrbiMed (an investment adviser and funds), not an individual executive; the filing includes standard disclaimers about beneficial ownership.
Insider Transaction Report
Form 4
ORBIMED ADVISORS LLC
Director
Transactions
- Purchase
Pre-Funded Warrants (right to buy)
[F1][F2][F3][F5]2026-06-11+1,041,667→ 26,519,541 total(indirect: See Footnote)Exercise: $0.00→ Common Stock (1,041,667 underlying) - Purchase
Pre-Funded Warrants (right to buy)
[F1][F2][F4][F5]2026-06-11+208,333→ 5,303,908 total(indirect: See Footnote)Exercise: $0.00→ Common Stock (208,333 underlying)
Holdings
- 5,255,106(indirect: See Footnote)
Common Stock
[F3][F5] - 1,051,021(indirect: See Footnote)
Common Stock
[F4][F5]
Footnotes (5)
- [F1]On June 9, 2026, the Issuer announced a public offering of an aggregate of 10,879,376 shares of common stock ("Shares") at a price of $4.00 per Share and, in lieu of Shares to certain investors, pre-funded warrants ("Pre-Funded Warrants") to purchase up to an aggregate of 7,870,624 Shares at a price of $3.9999 per Pre-Funded Warrant. The Pre-Funded Warrant have an exercise price of $0.0001 per share and are exercisable at any time after the date of issuance. The public offering closed on June 11, 2026.
- [F2]The Pre-Funded Warrants are exercisable at any time after the date of issuance, subject to a 9.99% beneficial ownership blocker. The Pre-Funded Warrants will expire once exercised in full.
- [F3]These securities are held of record by OrbiMed Private Investments IX, LP ("OPI IX"). OrbiMed Capital GP IX LLC ("GP IX") is the general partner of OPI IX. OrbiMed Advisors LLC ("OrbiMed Advisors"), a registered investment adviser under the Investment Advisers Act of 1940, as amended, is the managing member of GP IX. By virtue of such relationships, GP IX and OrbiMed Advisors may be deemed to have voting and investment power with respect to the securities held by OPI XI. OrbiMed Advisors exercises this investment and voting power through a management committee comprised of Carl L. Gordon, Sven H. Borho, and W. Carter Neild, each of whom disclaims beneficial ownership of the shares held by OPI IX.
- [F4]These securities are held of record by OrbiMed Genesis Master Fund, L.P. ("Genesis Master Fund"). OrbiMed Genesis GP LLC ("Genesis GP") is the general partner of Genesis Master Fund. OrbiMed Advisors is the managing member of Genesis GP. By virtue of such relationships, Genesis GP and OrbiMed Advisors may be deemed to have voting and investment power with respect to the securities held by Genesis Master Fund. OrbiMed Advisors exercises voting and investment power through a management committee comprised of Carl L. Gordon, Sven H. Borho, and W. Carter Neild, each of whom disclaims beneficial ownership of the shares held by Genesis Master Fund.
- [F5]This report on Form 4 is jointly filed by OrbiMed Advisors, GP IX, and Genesis GP. Each of the Reporting Persons disclaims beneficial ownership of the securities reported herein for purposes of Rule 16a-1(a) under the Securities Exchange Act of 1943, as amended (the "Exchange Act"), except to the extent of its pecuniary interest therein, if any. OrbiMed Advisors has designated a representative, Mona Ashiya ("Ashiya"), a member of OrbiMed Advisors, to serve on the Issuer's board of directors. This report shall not be deemed an admission that any of the Reporting Persons or Ashiya is a beneficial owner of such securities for purposes of Section 16 of the Exchange Act, or for any other purpose.